[go: up one dir, main page]

MX2013006059A - Metodo para tratar la piel con moduladores de microarn. - Google Patents

Metodo para tratar la piel con moduladores de microarn.

Info

Publication number
MX2013006059A
MX2013006059A MX2013006059A MX2013006059A MX2013006059A MX 2013006059 A MX2013006059 A MX 2013006059A MX 2013006059 A MX2013006059 A MX 2013006059A MX 2013006059 A MX2013006059 A MX 2013006059A MX 2013006059 A MX2013006059 A MX 2013006059A
Authority
MX
Mexico
Prior art keywords
methods
treating skin
microrna
active agents
skin
Prior art date
Application number
MX2013006059A
Other languages
English (en)
Other versions
MX345299B (es
Inventor
John W Lyga
Uma Santhanam
Permanan Raaj Khusial
Original Assignee
Avon Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avon Prod Inc filed Critical Avon Prod Inc
Publication of MX2013006059A publication Critical patent/MX2013006059A/es
Publication of MX345299B publication Critical patent/MX345299B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/17—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/46—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur
    • A61K8/466—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur containing sulfonic acid derivatives; Salts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
    • A61K8/4926—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having six membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/18—Antioxidants, e.g. antiradicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
    • A61K2800/782—Enzyme inhibitors; Enzyme antagonists
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/148—Screening for cosmetic compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Birds (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Se proveen métodos para prevenir, mejorar o reducir los signos dermatológicos del envejecimiento, que emplean agentes activos que suprimen o disminuyen la expresión de microARN en el fibroblasto dérmico, lo que da como resultado un incremento en la producción de colágeno, elastina y/o fibrilina en la piel. También se proveen métodos para detectar la actividad contra microARN específicos y métodos para utilizar agentes activos identificados mediante el protocolo de prueba en el tratamiento de la piel.
MX2013006059A 2010-12-28 2011-11-21 Uso de moduladores de microarn. MX345299B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12/979,695 US8455518B2 (en) 2010-12-28 2010-12-28 Method of treating skin with microRNA modulators
PCT/US2011/061656 WO2012091824A1 (en) 2010-12-28 2011-11-21 METHOD OF TREATING SKIN WITH microRNA MODULATORS

Publications (2)

Publication Number Publication Date
MX2013006059A true MX2013006059A (es) 2013-07-03
MX345299B MX345299B (es) 2017-01-24

Family

ID=46317882

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2013006059A MX345299B (es) 2010-12-28 2011-11-21 Uso de moduladores de microarn.
MX2017000916A MX367271B (es) 2010-12-28 2011-11-21 Uso de moduladores de microarn.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2017000916A MX367271B (es) 2010-12-28 2011-11-21 Uso de moduladores de microarn.

Country Status (12)

Country Link
US (2) US8455518B2 (es)
EP (2) EP2658537B1 (es)
JP (1) JP5918783B2 (es)
CN (2) CN103249409B (es)
AR (1) AR084598A1 (es)
BR (1) BR112013014597B1 (es)
CA (2) CA3010395C (es)
HU (1) HUE068372T2 (es)
MX (2) MX345299B (es)
PL (2) PL2658537T3 (es)
TW (1) TWI605833B (es)
WO (1) WO2012091824A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106727054A (zh) 2010-06-30 2017-05-31 雅芳产品公司 用于刺激magp‑1以改善皮肤外观的组合物和方法
US8815265B2 (en) * 2010-06-30 2014-08-26 Avon Products, Inc. Cosmetic use of N-substituted sulfonyloxybenzylamines and related compounds
US8632827B2 (en) 2011-12-13 2014-01-21 Avon Products, Inc Modulation of thymosin beta-4 in skin
JP6120398B2 (ja) * 2012-11-02 2017-04-26 国立大学法人三重大学 水溶性フィブリリン組成物による弾性線維増強法
US9186316B2 (en) 2012-12-11 2015-11-17 Avon Products, Inc. Stephanotis jasminoides extracts and methods of use
WO2014092686A1 (en) * 2012-12-11 2014-06-19 Avon Products, Inc. Stephanotis jasminoides extracts and methods of use
WO2014093053A1 (en) * 2012-12-11 2014-06-19 Avon Products, Inc. Modulation of thymosin beta-4 in skin
TW201422246A (zh) 2012-12-11 2014-06-16 Avon Prod Inc 藉由調節ｗｉｐｉ－１改善皮膚老化外觀之方法
US9445981B2 (en) 2012-12-20 2016-09-20 Avon Products, Inc PLOD-2 stimulators and their use in the treatment of skin
CN110205366B (zh) * 2018-02-28 2022-06-21 伽蓝（集团）股份有限公司 一种皮肤内源性老化靶标的筛选方法及改善皮肤内源性老化的活性物及其筛选方法
CN111041082B (zh) * 2018-10-11 2023-11-07 伽蓝（集团）股份有限公司 一种以皮肤光老化靶标筛选改善皮肤光老化的活性物的方法及改善皮肤光老化的活性物
CN111249466B (zh) * 2020-03-14 2022-04-15 浙江大学医学院附属第一医院 丹参酮ⅡA与miR-29b抑制剂联合在制备治疗肌腱粘连的药物中的应用
EP4380579A4 (en) * 2021-08-06 2025-06-11 Leadermed Champion Limited Mirna-based compositions and methods of use thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9918023D0 (en) * 1999-07-30 1999-09-29 Unilever Plc Skin care composition
IL161100A0 (en) 2001-09-28 2004-08-31 Max Planck Gesellschaft Identification of novel genes coding for small temporal rnas
UA82835C2 (en) * 2001-12-03 2008-05-26 Reddys Lab Ltd Dr ?-aryl-?-oxysubstituted propionuc acid derivatives and pharmaceutical composition based thereon
CA2554818A1 (en) 2004-02-09 2005-08-25 Thomas Jefferson University Diagnosis and treatment of cancers with microrna located in or near cancer-associated chromosomal features
WO2006133588A1 (en) * 2005-06-13 2006-12-21 Oncalis Ag ARYL UREA COMPOUNDS AS β-SECRETASE INHIBITORS
JP5192380B2 (ja) * 2005-09-08 2013-05-08 株式會社アモーレパシフィック 皮膚老化防止用皮膚外用剤組成物
MX2010001217A (es) 2007-07-31 2010-04-07 Regents The Unuversity Of Texa Familia de micro-arn que modula la fibrosis y usos de la misma.
JP5654347B2 (ja) * 2007-07-31 2015-01-14 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム ミオシンの発現及び筋線維の同一性を制御するマイクロｒｎａ
WO2011048004A1 (en) 2009-10-23 2011-04-28 Boehringer Ingelheim International Gmbh Inhibitors of the microsomal prostaglandin e2 synthase-1
US8815265B2 (en) * 2010-06-30 2014-08-26 Avon Products, Inc. Cosmetic use of N-substituted sulfonyloxybenzylamines and related compounds
CN106727054A (zh) * 2010-06-30 2017-05-31 雅芳产品公司 用于刺激magp‑1以改善皮肤外观的组合物和方法
CN103561718B (zh) * 2010-12-30 2020-06-16 雅芳产品公司 皮肤中动力蛋白的调节

Also Published As

Publication number Publication date
PL2987534T3 (pl) 2024-11-12
PL2658537T3 (pl) 2015-08-31
WO2012091824A1 (en) 2012-07-05
EP2658537B1 (en) 2015-04-29
CN103249409A (zh) 2013-08-14
CA3010395A1 (en) 2012-07-05
CN104622704A (zh) 2015-05-20
HK1206591A1 (en) 2016-01-15
CN103249409B (zh) 2016-07-06
JP2014509307A (ja) 2014-04-17
TWI605833B (zh) 2017-11-21
CN104622704B (zh) 2017-12-22
MX367271B (es) 2019-08-12
JP5918783B2 (ja) 2016-05-18
CA2817395A1 (en) 2012-07-05
MX345299B (es) 2017-01-24
EP2987534A1 (en) 2016-02-24
HUE068372T2 (hu) 2024-12-28
EP2987534B1 (en) 2024-07-10
CA3010395C (en) 2020-12-15
TW201231078A (en) 2012-08-01
CA2817395C (en) 2019-03-05
EP2658537A4 (en) 2014-06-25
BR112013014597A2 (pt) 2016-09-20
BR112013014597B1 (pt) 2020-06-30
EP2658537A1 (en) 2013-11-06
US20120165373A1 (en) 2012-06-28
HK1187251A1 (zh) 2014-04-04
US20130253053A1 (en) 2013-09-26
AR084598A1 (es) 2013-05-29
US8865740B2 (en) 2014-10-21
US8455518B2 (en) 2013-06-04

Similar Documents

Publication Publication Date Title
MX2013006059A (es) Metodo para tratar la piel con moduladores de microarn.
CY1121014T1 (el) ΝΕΑ ΔΟΜΙΚΑ ΣΧΕΔΙΑΜΕΝΑ shRNA
IN2015DN02938A (es)
GB2502029A (en) Cosmetic or pharmaceutical formulation
AR093386A1 (es) Composicion para tratar la diabetes o la diabesidad que comprende un analogo de oxintomodulina y metodo de tratamiento
ECSP13012869A (es) Compuestos y métodos para la modulación de quinasas e indicaciones para los mismos
WO2012110996A3 (en) A method and apparatus for cosmetic skin treatment
EA201490613A1 (ru) Соединения с замедляющим старение действием
AR080730A1 (es) Uso del fitocanabinoide canabidivarina (cbdv) en el tratamiento de la epilepsia
ES2533145R1 (es) Procedimiento cosmético para reducir el tejido adiposo subcutáneo
NI201300110A (es) Alfa glucosidasa ácida modificada con procesamiento acelerado
BRPI1000320B8 (pt) Composições e métodos para tratar sinais de envelhecimento da pele
UY34577A (es) Método para estabilizar fibra de lignina y su posterior conversión en fibra de carbono
BR112015010772A2 (pt) composição de enxágue tópica, uso de uma composição e método para tratar ou melhorar a pele de um indivíduo contra a acne
BR112014013172A2 (pt) extratos de maesa japonica e métodos de uso
BRPI1011912A2 (pt) l-serina para uso como medicamento para prevenir e/ou tratar uma reação inflamatória da pele.
GB201316955D0 (en) Composition comprising a diindolymethane and a retinoid to treat a skin condition
MX370166B (es) Composicion que comprende extracto de guacatonga y extracto de aroeira, uso de la misma para prevenir y/o tratar el envejecimiento de la piel.
HK1207308A1 (en) Method of utilizing azelaic acid esters to modulate communications mediated by biological molecules
EP2537513A3 (en) Use of anogeissus extract for fibrillin production in skin
BR112014028878A2 (pt) composição cosmética, método de tratamento cosmético da pele e uso de uma composição cosmética
TR201900863T4 (tr) Beta-klorosiklopentanların hidrofilik ester ön ilaçlarının kullanılmasıyla merkezi korneal kalınlaşmanın azaltılması.
BR112012022238A2 (pt) pele artificial
MX2015008997A (es) Moleculas pequeñas que promueven la regeneracion de la piel.
MX2012010382A (es) Modulacion de acuaporinas con relaxina.

Legal Events

Date Code Title Description
FG Grant or registration